Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes

Hector Garcia Garcia, Rohit Oemrawsingh, S Brugaletta, Pascal Vranckx, J Shannon, R Davies, Eric Boersma, PWJC (Patrick) Serruys

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


Objectives: We compared the incidence of late increase in hs-cTnI between ACS and non-ACS patients treated with standard of care with or without darapladib. Methods: A total of 323 (161 ACS and 162 non-ACS patients) were included. High sensitivity troponin I was measured at baseline and at 4, 13, 26 and 52 weeks. Results: ACS patients had statistically higher hs-cTnI values during longer term follow-up at which these patients were no longer in the acute setting of myocardial ischemia, but were regarded to have stable CAD (mean hsTnI value in ACS patients: 1.180 versus 0.886 ng/L in non-ACS patients, p = 0.02). Multivariate logistic regression revealed three predictors of any 2-fold increase in hs-cTnI levels compared to the previous visit when interactions were not considered. Treatment with darapladib ( Conclusion: In patients with ACS, treatment with darapladib is associated with less increase in cardiac troponin I compared to standard of care alone. This beneficial effect may be associated with darapladib's capability of reducing necrotic core in coronary plaques. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)142-147
Number of pages6
Issue number1
Publication statusPublished - 2012

Research programs

  • EMC COEUR-09

Cite this